摘要
肝细胞癌(hepatocellular carcinoma,HCC)合并门静脉癌栓(portal vein tumor thrombus,PVTT),尤其是Ⅳ型癌栓者难治疗、预后差。本文报道1例初诊确诊为HCC合并Ⅲ型PVTT患者,经肝动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)1次+射频消融治疗(radiofrequency ablation,RFA)1次+索拉非尼(400 mg,每日2次)治疗1个月后进展为HCC合并Ⅳ型癌栓,经乐伐替尼(12 mg,每日1次)治疗1个月达肿瘤降期,再次联合TACE治疗1次+RFA治疗1次,肿瘤评估完全缓解(complete remission,CR)。
Patients of hepatocellular carcinoma(HCC)with portal vein tumor thrombus(PVTT),especially those with type Ⅳ PVTT were difficult to treat and the prognosis was poor.This paper reported a newly diagnosed case of HCC with type Ⅲ PVTT,who was treated by transcatheter arterial chemoembolization(TACE)one time + radiofrequency ablation(RFA)one time + sorafenib(400 mg,twice per day)for one month,then the case progressed to type Ⅳ PVTT and received lenvatinib(12 mg,once per day)for one month,and the stage of tumor descended.The patient received TACE(one time)+ RFA(one time)again,and the tumor assessment reached complete remission(CR).
作者
张海娇
刘晓民
孙巍
魏建莹
陈京龙
ZHANG Hai-jiao;LIU Xiao-min;SUN Wei;WEI Jian-ying;CHEN Jing-long(Center of Internal Medicine Oncology,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China)
出处
《中国肝脏病杂志(电子版)》
CAS
2019年第1期85-89,共5页
Chinese Journal of Liver Diseases:Electronic Version
基金
首都临床特色应用研究与成果推广(Z161100000516141)
关键词
肝细胞癌
局部治疗
索拉非尼
乐伐替尼
Hepatocellular carcinoma
Locoregional therapy
Sorafenib
Lenvatinib